Welcome to our dedicated page for Xbiotech SEC filings (Ticker: XBIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XBiotech Inc. filings document governance, executive-compensation, shareholder-vote, and material-agreement disclosures for a British Columbia biopharmaceutical issuer. Recent Form 8-K reports cover board appointments, committee assignments, amendments to director information, executive employment arrangements, and annual meeting voting results.
The company’s proxy materials describe director elections, auditor ratification, advisory compensation votes, and equity incentive plan matters. These filings provide the formal record for XBiotech’s board structure, compensation oversight, shareholder voting mechanics, and related public-company governance actions.
XBiotech announced two significant appointments to its Board of Directors on June 24, 2025. The company has appointed Dr. Thomas Kündig and Craig Rademaker as new board members, with immediate effect until the 2025 Annual General Meeting.
Key appointments and roles:
- Dr. Kündig, Director of Dermatology at University Hospital Zurich, joins the Compensation Committee. He brings expertise in immunodermatology and pioneering work in intralymphatic immunotherapy (ILIT)
- Mr. Rademaker, a financial industry veteran with 25+ years experience, joins the Audit Committee. He currently leads a Private Equity firm managing assets over $5 billion
The updated committee structure now includes:
- Audit Committee: Jan-Paul Waldin, Dr. Peter Libby, and Craig Rademaker
- Compensation Committee: Jan-Paul Waldin, Dr. Peter Libby, and Dr. Thomas Kündig